Hemostemix Financials

HEM Stock  CAD 0.08  0.01  5.88%   
We strongly advise to harness Hemostemix fundamental analysis to find out if markets are presently mispricing the company. Simply put you can make use of it to find out if Hemostemix is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to interpolate twenty-three available reported financial drivers for Hemostemix, which can be compared to its competitors. The stock experiences a very speculative upward sentiment. Check odds of Hemostemix to be traded at C$0.076 in 90 days. Key indicators impacting Hemostemix's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.10.109
Significantly Down
Slightly volatile
  
Understanding current and past Hemostemix Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Hemostemix's financial statements are interrelated, with each one affecting the others. For example, an increase in Hemostemix's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Hemostemix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Hemostemix. Check Hemostemix's Beneish M Score to see the likelihood of Hemostemix's management manipulating its earnings.

Hemostemix Stock Summary

Hemostemix competes with VentriPoint Diagnostics. Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. HEMOSTEMIX INC is traded on TSX Venture Exchange in Canada.
Foreign Associate
  USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeTSX Venture Exchange
ISINCA4236943060
Business Address707-7th Avenue SW,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitehemostemix.com
Phone905 580 4170
CurrencyCAD - Canadian Dollar
You should never invest in Hemostemix without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Hemostemix Stock, because this is throwing your money away. Analyzing the key information contained in Hemostemix's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Hemostemix Key Financial Ratios

There are many critical financial ratios that Hemostemix's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Hemostemix reports annually and quarterly.

Hemostemix Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets104.3K2.3M563.0K465.3K313.8K298.1K
Other Current Liab2.1M3.2M1.0M2.6M3.0M3.2M
Net Tangible Assets487.8K(4.0M)(1.1M)(6.8M)(6.1M)(5.8M)
Net Debt2.0M(83.0K)1.3M4.0M4.2M4.4M
Retained Earnings(41.5M)(49.2M)(55.5M)(60.8M)(63.3M)(60.1M)
Accounts Payable2.1M3.2M4.4M2.4K2.9M1.6M
Cash24.1K258.0K219.4K135.7K155.4K147.6K
Net Receivables75.8K2.1M342.7K138.9K25.1K23.8K
Inventory(88.2K)(13.3K)(45.5K)(342.7)(394.1)(413.81)
Other Current Assets13.3K45.5K342.7190.3K133.1K101.6K
Total Liab4.1M3.4M5.8M7.2M7.7M8.1M
Total Current Assets99.8K2.3M562.1K464.9K313.6K297.9K
Net Invested Capital(2.0M)(923.7K)(3.8M)(2.6M)(3.0M)(2.9M)
Net Working Capital(4.0M)(1.1M)(3.8M)(2.2M)(2.6M)(2.4M)

Hemostemix Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense105.0K106.0K10.5K350.3K550.1K577.6K
Operating Income(4.7M)(7.5M)(6.7M)(4.6M)(2.2M)(2.3M)
Ebit(4.7M)(7.5M)(6.7M)(4.6M)(2.2M)(2.3M)
Research Development2.4M650.1K179.9K622.7K384.9K365.6K
Ebitda(4.7M)(7.5M)(6.7M)(4.6M)(2.2M)(2.3M)
Income Before Tax(4.9M)(7.8M)(6.5M)(4.7M)(2.5M)(2.6M)
Net Income(4.9M)(7.8M)(6.3M)(5.2M)(2.5M)(2.6M)
Income Tax Expense105.0K106.0K(255.8K)486.9K(3.0)(2.85)
Net Interest Income(105.0K)(113.0K)(20.9K)(354.0K)(556.1K)(528.3K)

Hemostemix Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash(1.4M)233.9K(38.5K)(83.7K)19.7K20.7K
Free Cash Flow(3.4M)(6.0M)(3.5M)(6.1M)(1.5M)(1.6M)
Other Non Cash Items105.0K106.0K(114.3K)172.8K335.9K352.7K
Net Income(4.9M)(7.8M)(6.3M)(5.2M)(2.5M)(2.6M)
End Period Cash Flow24.1K258.0K219.4K135.7K155.4K147.6K
Change To Netincome1.6M438.2K2.6M838.4K964.1K1.0M

Hemostemix Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Hemostemix's current stock value. Our valuation model uses many indicators to compare Hemostemix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hemostemix competition to find correlations between indicators driving Hemostemix's intrinsic value. More Info.
Hemostemix is rated below average in return on asset category among its peers. It is rated # 4 in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemostemix's earnings, one of the primary drivers of an investment's value.

Hemostemix Systematic Risk

Hemostemix's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Hemostemix volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Hemostemix correlated with the market. If Beta is less than 0 Hemostemix generally moves in the opposite direction as compared to the market. If Hemostemix Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Hemostemix is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Hemostemix is generally in the same direction as the market. If Beta > 1 Hemostemix moves generally in the same direction as, but more than the movement of the benchmark.

Hemostemix Total Assets Over Time

Today, most investors in Hemostemix Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Hemostemix's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Hemostemix growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0369

At this time, Hemostemix's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Hemostemix November 24, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Hemostemix help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Hemostemix. We use our internally-developed statistical techniques to arrive at the intrinsic value of Hemostemix based on widely used predictive technical indicators. In general, we focus on analyzing Hemostemix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Hemostemix's daily price indicators and compare them against related drivers.

Additional Tools for Hemostemix Stock Analysis

When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.